Veritas is set to make a significant impact at the upcoming European Society of Human Genetics (ESHG) Congress 2024 in Berlin from June 1 to 4. Demonstrating their commitment to preventive medicine and genomic screening, Veritas will unveil two groundbreaking studies alongside their cutting-edge polygenic risk service, myHealthScore, designed to assess genetic predispositions to common adult diseases.
The ESHG Congress serves as a premier platform for sharing the latest advancements in human genetics, fostering education, and facilitating knowledge exchange through plenary sessions, symposia, workshops, and poster presentations.
Veritas will showcase their latest services and innovations in preventive medicine. Among their presentations, the first study focuses on Genomic Newborn Screening, offering insights into the clinical experience in Spain with exome sequencing of 800 newborns. Led by Dr. Vincenzo Cirigliano, Chief Technical Officer, this research signifies a pivotal step in early genomic diagnostics.
The second study, spearheaded by Dr. Luis Izquierdo, Chief Medical Officer, delves into Elective Genome Screening, involving 1300 healthy individuals. Using Veritas’ myGenome test, this study provides valuable insights into genetic predispositions based on ACMG-SF and ACOG guidelines, pharmacogenomics, and multifactorial diseases.
A highlight of Veritas’ offerings is the myHealthScore, a polygenic risk assessment service designed to identify genetic risks for various common diseases, including cardiovascular diseases, type 2 diabetes, breast cancer, and prostate cancer. By leveraging genetic insights, Veritas aims to empower individuals to proactively manage their health through personalized preventive strategies and lifestyle modifications.
Veritas, as a global leader in genomic diagnostics, is dedicated to extending and enhancing lives through science-driven solutions. Their recent collaboration with Letsgetchecked further strengthens their position in the global health solutions landscape. Through partnerships with healthcare providers, governments, and communities worldwide, Veritas remains steadfast in its mission to democratize access to reliable and affordable genetic and genomic medicine.